Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO

Last updated: October 29, 2019
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Esophageal Disorders

Digestive System Neoplasms

Treatment

N/A

Clinical Study ID

NCT04137679
TJESO-1
  • Ages 18-70
  • All Genders

Study Summary

Definitive chemoradiotherapy(CRT) has been regarded as a standard of care for patients with unresectable locally advanced esophageal cancer. Patients who are sensitive to CRT can achieve significantly down staging. Whether this part of patients could benefit from further surgical treatment remains unknown. Herein, a single center prospective randomized phase II clinical trial will be carried out to compare efficacy and safety of definitive CRT versus neo-CRT plus radical resection in patients who achieved down staging after neo-CRT for stage T4NxM0 esophageal Cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Thoracic esophageal cancer patients or esophagogastric junction cancer patients, withlocally advanced unresectable tumor, clinically identified before treatment as T4bNxM0or lymph node metastases (LNM)invading adjacent structures according toUICC(International Union Against Cancer) TNM(primary tumor, regional nodes,metastasis) Classification of Malignant Tumours, 8th ed.

  2. Initial unresectable assessed by surgeon.

  3. Patients able to tolerate surgery.

  4. Untreated patients who have not received any antitumor therapy.

  5. Life expectancy > 6 months.

  6. Age: 18-70 years.

  7. White blood cell count ≥4.0×10^9/L, ANC(absolute neutrophil count) ≥1.5×10^9/L,thrombocyte count ≥100×10^9/L, hemoglobin ≥90 g/L; normal liver and kidney functions.

  8. WHO PS(Performance Status): 0-1.

  9. Patients who understood the study and gave signed informed consent.

Exclusion

Exclusion Criteria:

  1. Patients who have already received antitumor therapy, including chemotherapy,radiotherapy or surgery.

  2. Patients with hemorrhage or complicated hemorrhage.

  3. Other uncontrollable patients who are not suitable for surgery.

  4. Patients who deny to accept surgery.

  5. Pregnant or lactating women.

  6. Patients who agree without acknowledgement as a result of psychological, family orsocial factors.

  7. Patients with CTCAE(Common Terminology Criteria Adverse Events Version 4.0) grade ≥2peripheral neuropathy.

  8. Patients who have ever had malignant tumors other than esophageal cancer.

  9. Patients with a history of diabetes for >10 years with unsatisfactory control of bloodglucose level.

  10. Patients with serious heart, lung, liver or kidney dysfunction, hematopathy, immunesystem disease or cachexia who therefore cannot tolerate chemotherapy or surgery.

  11. Patients with severe infection.

  12. Patients with uncontrolled diabetes, random blood glucose > 200mg/L, fasting glucose >140mg/L.

  13. Patients with other severe disease, such as myocardial infarction in the last 6months.

  14. Patients who participate in other clinical trials right now or in the last 4 weeks.

Study Design

Total Participants: 60
Study Start date:
November 01, 2019
Estimated Completion Date:
August 31, 2022

Study Description

  1. Compare progression-free survival (PFS) and overall survival (OS) of definitive radiochemotherapy versus(VS) neoadjuvant radiochemotherapy plus radical resection for esophageal cancer patients who down stage from inoperable to operable after neoadjuvant treatment;

  2. Compare the toxic and side effects of definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus radical resection for esophageal cancer patients who achieved clinical complete remission after neoadjuvant treatment;

  3. Assess impact of definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus radical resection on quality of life of patients.

Concurrent Radiochemotherapy: Radiotherapy, Intensity Modulation Radiation Therapy(IMRT), 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2), 1st/8th/15th/22nd day

Connect with a study center

  • Department of Radiation Oncology, Tianjin Medical University Cancer Hospital

    Tianjin, Tianjin 300060
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.